Insulin Glargine Shortage: What Providers and Prescribers Need to Know in 2026

The Insulin Glargine market in 2026 is presenting prescribers with a complex set of challenges: a major biosimilar has exited the market, a pen format is being discontinued, insurance formularies are in flux, and patients are confused and anxious. This guide synthesizes what you need to know clinically and operationally to manage your patients through this transition.

The Semglee Discontinuation: Clinical Implications

Semglee (insulin glargine-yfgn), the first FDA-designated interchangeable biosimilar to Lantus, was discontinued by Biocon Biologics effective December 31, 2025. This has created an immediate need to transition all Semglee patients to a new product.

Key clinical points:

• Semglee was FDA-designated as interchangeable with Lantus, meaning pharmacists could previously substitute without prescriber intervention. Now that Semglee is discontinued, patients need explicit new prescriptions.
• Dose equivalence: Lantus, Basaglar, Rezvoglar, and generic Insulin Glargine (all U-100) are dose-equivalent — 1:1 unit conversion. No titration is required for these switches.
• Switching to Toujeo (U-300) is NOT 1:1. A starting dose of 80% of the current U-100 dose may be appropriate when converting from U-100 to U-300. Monitor closely for the first 5–7 days.
• Proactively identify all patients with active Semglee prescriptions in your EHR and reach out before they run out of insulin.

Available Insulin Glargine Products in 2026

For clinical reference, here are the currently available Insulin Glargine products and their characteristics:

• Lantus (glargine) U-100 — Sanofi: Reference product; vials and SoloStar pens; widely available; $35/month Sanofi program
• Toujeo (glargine) U-300 — Sanofi: Concentrated; SoloStar and Max SoloStar pens; NOT 1:1 with U-100; longer, flatter PK; $35/month Sanofi program
• Basaglar (glargine) U-100 — Eli Lilly: KwikPen (Tempo pen discontinued end of 2026); generally good availability; $35/month Lilly program
• Rezvoglar (glargine-aglr) U-100 — Eli Lilly: FDA-interchangeable biosimilar; growing availability; $35/month Lilly program
• Langlara (glargine-aldy) U-100 — Sunshine Lake/Lannett: Newest interchangeable biosimilar; FDA-approved May 4, 2026; entering market
• Generic Insulin Glargine U-100: Available from Winthrop and other manufacturers; often lowest retail price

Navigating the Prior Authorization Surge

As insurance plans update their formularies following the Semglee discontinuation, many practices are experiencing a surge in prior authorization requests for brand Lantus and Basaglar. Strategies to manage this burden:

• Pre-emptively document clinical rationale for Insulin Glargine in patient charts when you first prescribe it. This expedites PA requests.
• For urgent cases, request emergency/urgent PA review — most insurers have a 24–72 hour pathway for medically urgent situations like insulin access.
• Inform patients about the Sanofi Valyou Savings Program ($35/month for Lantus/Toujeo) as a bridge while PA processes are completed.
• Some Blue Cross plans issued guidance in 2025 allowing pharmacist Lantus substitution for Semglee without new prescriptions — verify your patients' plan-specific rules.

Managing the Basaglar Tempo Pen Transition

Eli Lilly announced in late 2025 that the Basaglar Tempo pen will be discontinued by the end of 2026, with availability through July 27, 2026. For patients on Basaglar Tempo pens:

• Issue new prescriptions for Basaglar KwikPen, which delivers doses in the same 1-unit increments from 1 to 80 units
• Educate patients that the KwikPen looks different but contains the same insulin glargine at the same concentration — dose conversion is 1:1
• Identify these patients in your EHR now and proactively issue new prescriptions before July 2026

Communicating Effectively with Patients

Patients are confused by the proliferation of Insulin Glargine products and the discontinuation of Semglee. Clear, proactive communication from your office can prevent missed doses and unnecessary ER visits. Consider:

• Sending a portal message or automated phone call to all Semglee patients explaining the switch
• Reassuring patients that Lantus, Basaglar, and Rezvoglar are dose-equivalent to Semglee at the same concentration
• Recommending medfinder.com to help patients locate whichever insulin glargine product is covered and in stock near them

How medfinder Can Help Your Practice

medfinder offers a provider-facing tool that lets your staff check real-time Insulin Glargine availability at pharmacies in your patients' areas. Instead of spending staff time calling pharmacies, you can direct patients to medfinder.com/providers to learn more.

For a hands-on clinical reference, also see our provider's guide to helping patients find Insulin Glargine in stock.